Krystal Biotech, Inc.
KRYS
株式のランク
#2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
株価
$326.41
時価総額
$9.66B
変化（1日）
1.92%
変化（1年）
66.57%
国
US
取引 Krystal Biotech, Inc. (KRYS)
カテゴリー
Healthcare
Krystal Biotech, Inc.（KRYS）の発行済株式数
June 2026 時点の発行済株式数 29.53M
Krystal Biotech, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 29.53M です。December 2023 の終わりには、同社は 27.15M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Krystal Biotech, Inc.（KRYS）の発行済株式数の履歴（2016 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 29.53M | 3.28% |
| 2024 | 28.59M | 5.30% |
| 2023 | 27.15M | 6.52% |
| 2022 | 25.49M | 14.85% |
| 2021 | 22.20M | 18.15% |
| 2020 | 18.79M | 18.15% |
| 2019 | 15.90M | 41.93% |
| 2018 | 11.20M | 108.99% |
| 2017 | 5.36M | 25.38% |
| 2016 | 4.28M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 759.83% |
US
|
|
| 396.00M | 1,241.05% |
US
|
|
| 478.91M | 1,521.84% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 110.59% |
NL
|
